Form 4: Gilead Sciences Director Acquires Stock Options

Gilead Sciences Director Ted W. Love acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Summary

• Ted W. Love, a Director at Gilead Sciences, Inc., acquired 1,146 restricted stock units (RSUs) and a non-qualified stock option for 4,884 shares.
• The RSUs were granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan and vested immediately on April 30, 2026.
• The stock option also vested immediately on April 30, 2026, with an exercise price of $130.84 per share.
• Following these transactions, Love beneficially owns 5,484 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine equity grants to a director rather than significant financial performance updates or strategic shifts.

Positives

• Director Love received equity awards, indicating continued alignment with shareholder interests.
• Immediate vesting of RSUs and stock options suggests a commitment to long-term engagement.
• The acquisition of 1,146 RSUs and 4,884 stock options represents a significant grant.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily details a director's equity transactions.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a common practice in the biopharmaceutical industry to incentivize leadership and align their interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The equity grants to Director Love are intended to align his interests with those of shareholders, potentially leading to decisions that enhance long-term company value.

Key Dates

Keywords

Gilead Sciences, GILD, Form 4, SEC Filing, Stock Options, Restricted Stock Units, Equity Incentive Plan, Director Compensation, Beneficial Ownership